Trial Profile
Study of Pembrolizumab in Advanced or Metastatic Melanoma :Portuguese National Cancer Registry
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms RON
- 26 Oct 2020 Results published in the Pharmacoepidemiology and Drug Safety
- 28 Nov 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research